Healthy volunteers help measure how well cizutamig absorbs under the skin
NCT ID NCT07236411
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This early-stage study in 24 healthy adults aims to measure how much of the experimental drug cizutamig reaches the bloodstream when given as a shot under the skin compared to directly into a vein. Participants will receive either the drug or a placebo and be monitored for side effects and drug levels. The study does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cizutamig
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new experimental pill be safely given to people?
- Can a new injectable drug safely tackle weight? an early trial seeks answers
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- Scientists map brain changes during Hour-Long DMT experience
- First human trial launches for experimental drug BY002
- New drug BW-50218 put to first safety test in healthy chinese volunteers